Research Paper Volume 12, Issue 2 pp 1285—1303

DNAH10 mutation correlates with cisplatin sensitivity and tumor mutation burden in small-cell lung cancer

Figure 1. (A) IC50 distribution for cisplatin by tissue type. (B) Scatter plot of IC50 distribution for cisplatin in 55 SCLC cells. The red line shows the maximum screening concentration of 10.0 μM. DNAH10 mutant cell lines are highlighted in red. (C) Venn diagram showing the overlapping among genes predicted using the GDSC dataset and 101 patients with SCLC (reported by George et al). Abbreviation: IC50: half maximal inhibitory concentration; SCLC: Small-cell lung cancer; GDSC: The Genomics of Drug Sensitivity in Cancer Project (D) IC50 values for cisplatin in GDSC-SCLC cell lines with or without DNAH10 mutation. SCLC: Small-cell lung cancer; GDSC: The Genomics of Drug Sensitivity in Cancer Project.